Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.

(HealthDay News) — During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company’s high prices for its blockbuster ...

Europe's STOXX 600 share index closed at a record high on Friday as companies and sectors exposed to China continued to rally ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

Sima Sistani, CEO of WeightWatchers, announced her departure from the weight-loss company, which has struggled to adapt in ...

On Capitol Hill lawmakers grilled the CEO of the company that makes popular weight loss drugs Ozempic and Wegovy.

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...